Seeing Article 3(d) with 2020 vision
Read more >
Featured Insights: Biotechnology & Pharmaceuticals
Option is a failure with combination SPCs
Read more >
What does the US-China trade deal mean for pharmaceutical patent holders?
Read more >
Patents are only part of the pharma picture
Read more >
Antibodies at the European Patent Office
Read more >
Supplementary Protection Certificate (SPC) Manufacturing Waiver – Article 5 goes epic
Read more >
Third time lucky? EPO Enlarged Board of Appeal referred issue of plant patentability again
Read more >
Lost in translation: Are animal models predictive of a treatment effect?
Read more >
Substance or device – a distinction without a difference?
Read more >
Plausibility and non-working embodiments
Read more >
US claim construction at the English High Court – Chugai Pharmaceuticals Co. Ltd v U...
Read more >
Is there a high chance of US and UK courts grappling with medicinal cannabis patents?
Read more >
CJEU rules that mutated organisms are covered by the GMO Directive
Read more >
Kymouse’s stay of execution
Read more >
Regeneron v Kymab – Part 1: Sufficiency
Read more >
Regeneron v Kymab – Part II: Interpretation and Infringement
Read more >
Validation of European Patents for Cambodia
Read more >
Formally granted marketing authorisation required for SPC applications
Read more >
“Obvious to try” and clinical trials: Actavis v ICOS
Read more >
New pills instead of windmills – European Medicine Agency to relocate to Amsterdam
Read more >
